APOBEC3B and diffuse large B-cell lymphoma: In this study, we demonstrated that aberrantly activated APOBEC3B can induce TP53 G/C-to-A/T mutations in DLBCL, which may lead to proliferation and drug resistance and may contribute to R/R DLBCL.